Renovion
Phase 2Renovion is developing a new nebulizer therapy to treat lung mucus and improve lung function for patients of lung transplant, non-cystic fibrosis bronchiectasis (NCFBE), non-tuberculous mycobacteria-lung disease (NTM-LD), and Tracheostomy.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $14.5M
About
Renovion is developing a new nebulizer therapy to treat lung mucus and improve lung function for patients of lung transplant, non-cystic fibrosis bronchiectasis (NCFBE), non-tuberculous mycobacteria-lung disease (NTM-LD), and Tracheostomy.
Drug DeliverySmall Molecules
Funding History
2Total raised:$14.5M
Series A$12MSep 15, 2021
Seed$2.5MMay 15, 2019